KA‑EX successfully closes record crowdinvesting round on CONDA.ch
The crowd investing campaign of KA‑EX on CONDA.ch has been successfully completed – sending a strong signal for functional nutrition “made in Switzerland”. In total, CHF 4,788,300 was raised from 1,600 investors, clearly exceeding the original funding target.
KA‑EX: functional nutrition powered by patented technology
KA‑EX is a Swiss functional nutrition company focused on science‑backed products for recovery, sleep quality and stress reduction. At the heart of the portfolio is a patented blend of bioactive substances that has proven itself in professional sports, everyday life and nightlife.
Beyond its well‑known recovery drinks, KA‑EX relies on its proprietary VICAP dual‑chamber technology: a technology platform that keeps sensitive active ingredients separate and mixes them into the liquid only at the moment of consumption, ensuring stability and efficacy.
Strong traction in Switzerland – successful entry into the US market
In recent years, KA‑EX has built a leading market position in Switzerland. The products are available nationwide across retail channels, pharmacies, gyms and vending networks and are used by professionals as well as everyday consumers.
At the same time, the company is accelerating its international expansion. After initial success in Europe, the US market was identified as a key growth driver. Market entry in the United States has been executed with a strong focus on e‑commerce and fitness/retail partners and forms the basis for the next scaling phase.
Pre‑Series B as last opportunity before the next growth stage
The now closed pre‑Series B round was deliberately positioned as the last opportunity for private investors before KA‑EX moves into its next major growth phase. The financing aimed to secure additional growth capital for nationwide scaling in the US and for further development of the VICAP technology platform.
For investors, this represented an entry point at which key milestones were already validated: proven products, demonstrable market traction and a clear roadmap for the coming years. Demand was very strong – the round was oversubscribed and closed ahead of schedule.
Two revenue streams: brand and technology
KA‑EX generates revenue on the one hand through sales of its products – in brick‑and‑mortar retail, via online channels, in gyms and through international distribution partners. On the other hand, the company monetises its VICAP technology via contract manufacturing and co‑branding partnerships with third‑party brands.
This gives KA‑EX a hybrid business model that combines a consumer brand with a technology platform, enabling faster scaling and improved profitability.
Clear exit perspective for 2027/2028
Within its financing strategy, KA‑EX openly communicates a targeted exit window between 2027 and 2028, for example through a trade sale to a strategic buyer in the fields of functional beverages, nutrition or consumer health. Following the pre‑Series B, further growth steps are intended to be financed primarily through operating cash flow, with the planned Series B seen as the final equity financing round.
For investors, this results in a transparent risk/return profile with a clearly defined time horizon and scalable growth levers across both product and technology.
CONDA.ch as a bridge between growth companies and community
With this successful campaign, CONDA.ch reinforces its role as a leading crowd investing platform for growth companies in Switzerland. More than 1,600 people have invested in KA‑EX and have thus become co‑owners of an established functional nutrition player.
CONDA.ch connects startups and investors through digital processes, standardised information and a community‑driven investment culture. For companies like KA‑EX, this means access to growth capital, increased visibility and a committed fan base that actively supports the brand and its products.
Outlook
With the pre‑Series B round completed, KA‑EX is financially and strategically well positioned to tackle its next milestones: nationwide scaling in the US, further development of the VICAP technology platform and preparation for a potential exit transaction in the coming years.
Anyone who wants to follow KA‑EX on this journey and dive deeper into the investment story can find full details on the closed crowd investing round, the company and the technology on the dedicated campaign page at CONDA.ch: CONDA.ch/kaex3.
